Dr. Amaia Lujambio got her PhD at the Spanish National Cancer Center (Centro Nacional de Investigaciones Oncológicas, CNIO, Madrid) studying the epigenetic regulation of microRNAs in cancer in Manel Esteller´s laboratory. She then pursued her postdoctoral studies in Scott Lowe´s laboratory, where she demonstrated that p53 can suppress liver tumorigenesis through non-cell-autonomous mechanisms by modulating macrophage polarization and tumor microenvironment, highlighting the importance that the immune cell compartment has in liver cancer (1). The focus of the Lujambio laboratory is to better understand the mechanisms of liver cancer initiation and liver cancer maintenance by using sophisticated mouse models of cancer, RNA interference and CRISPR technology, valuable human samples, and genetic and immune profiling as key tools. Her lab has established that palbociclib, a selective CDK4/6 inhibitor, is effective in preclinical models of hepatocellular carcinoma and could be a promising strategy for RB1-positive HCC patients (2). More recently, her lab has created a novel mouse model of liver cancer to interrogate mechanisms of immune escape and response to immunotherapies (3). The ultimate goal is to improve our understanding of liver cancer and to identify novel strategies that can be exploited therapeutically to improve healthspan and longevity.